These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 21443940)

  • 21. Upflow anaerobic sludge blanket reactor--a review.
    Bal AS; Dhagat NN
    Indian J Environ Health; 2001 Apr; 43(2):1-82. PubMed ID: 12397675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody therapeutics, antibody engineering, and the merits of protein stability.
    Demarest SJ; Glaser SM
    Curr Opin Drug Discov Devel; 2008 Sep; 11(5):675-87. PubMed ID: 18729019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Minimalist active-site redesign: teaching old enzymes new tricks.
    Toscano MD; Woycechowsky KJ; Hilvert D
    Angew Chem Int Ed Engl; 2007; 46(18):3212-36. PubMed ID: 17450624
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmaceutical and industrial protein engineering: where we are?
    Amara AA
    Pak J Pharm Sci; 2013 Jan; 26(1):217-32. PubMed ID: 23261751
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Engineered affinity proteins--generation and applications.
    Grönwall C; Ståhl S
    J Biotechnol; 2009 Mar; 140(3-4):254-69. PubMed ID: 19428722
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Engineering proteins with tunable thermodynamic and kinetic stabilities.
    Pey AL; Rodriguez-Larrea D; Bomke S; Dammers S; Godoy-Ruiz R; Garcia-Mira MM; Sanchez-Ruiz JM
    Proteins; 2008 Apr; 71(1):165-74. PubMed ID: 17932922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody engineering and modification technologies.
    Filpula D
    Biomol Eng; 2007 Jun; 24(2):201-15. PubMed ID: 17466589
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Creating the next generation of protein therapeutics through rational drug design.
    Szymkowski DE
    Curr Opin Drug Discov Devel; 2005 Sep; 8(5):590-600. PubMed ID: 16159021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bioactive proteinaceous hydrogels from designed bifunctional building blocks.
    Wheeldon IR; Barton SC; Banta S
    Biomacromolecules; 2007 Oct; 8(10):2990-4. PubMed ID: 17887795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monoclonal antibodies as targeting and therapeutic agents: prospects for liver transplantation, hepatitis and hepatocellular carcinoma.
    Luk JM; Wong KF
    Clin Exp Pharmacol Physiol; 2006; 33(5-6):482-8. PubMed ID: 16700883
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravail: highly effective intranasal delivery of peptide and protein drugs.
    Maggio ET
    Expert Opin Drug Deliv; 2006 Jul; 3(4):529-39. PubMed ID: 16822227
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systems approach to therapeutics design.
    Lao BJ; Kamei DT
    Methods Mol Biol; 2009; 500():221-36. PubMed ID: 19399427
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved Pruning algorithms and Divide-and-Conquer strategies for Dead-End Elimination, with application to protein design.
    Georgiev I; Lilien RH; Donald BR
    Bioinformatics; 2006 Jul; 22(14):e174-83. PubMed ID: 16873469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimizing scaleup yield for protein production: Computationally Optimized DNA Assembly (CODA) and Translation Engineering.
    Hatfield GW; Roth DA
    Biotechnol Annu Rev; 2007; 13():27-42. PubMed ID: 17875472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size.
    Zahnd C; Kawe M; Stumpp MT; de Pasquale C; Tamaskovic R; Nagy-Davidescu G; Dreier B; Schibli R; Binz HK; Waibel R; Plückthun A
    Cancer Res; 2010 Feb; 70(4):1595-605. PubMed ID: 20124480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Monoclonal antibodies and therapeutics].
    Desgranges C
    Pathol Biol (Paris); 2004 Jul; 52(6):351-64. PubMed ID: 15261379
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advances in protein therapeutics.
    Woodnutt G; Violand B; North M
    Curr Opin Drug Discov Devel; 2008 Nov; 11(6):754-61. PubMed ID: 18946840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advancing mammalian cell culture engineering using genome-scale technologies.
    Griffin TJ; Seth G; Xie H; Bandhakavi S; Hu WS
    Trends Biotechnol; 2007 Sep; 25(9):401-8. PubMed ID: 17681628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Engineering a pharmacologically superior form of granulocyte-colony-stimulating factor by fusion with gelatin-like-protein polymer.
    Huang YS; Wen XF; Wu YL; Wang YF; Fan M; Yang ZY; Liu W; Zhou LF
    Eur J Pharm Biopharm; 2010 Mar; 74(3):435-41. PubMed ID: 19995603
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancement of therapeutic protein in vivo activities through glycoengineering.
    Elliott S; Lorenzini T; Asher S; Aoki K; Brankow D; Buck L; Busse L; Chang D; Fuller J; Grant J; Hernday N; Hokum M; Hu S; Knudten A; Levin N; Komorowski R; Martin F; Navarro R; Osslund T; Rogers G; Rogers N; Trail G; Egrie J
    Nat Biotechnol; 2003 Apr; 21(4):414-21. PubMed ID: 12612588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.